Results 51 to 60 of about 2,579,690 (304)

Systematic review of psychosocial outcomes for patients with advanced melanoma

open access: yes, 2017
BackgroundNew advanced melanoma therapies are associated with improved survival; however, quality of survivorship, particularly psychosocial outcomes, for patients overall and those treated with newer therapies is ...
Hyde, Melissa K   +5 more
core   +1 more source

PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells [PDF]

open access: yes, 2011
PAX transcription factors play an important role during development and carcinogenesis. In this study, we investigated PAX2 protein levels in melanocytes and melanoma cells by Western Blot and immunofluorescence analysis and characterized the role of ...
Ungerer Christopher   +50 more
core   +2 more sources

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study

open access: yesCancer Management and Research, 2021
Johannes Kleemann, Manuel Jäger, Eva Valesky, Stefan Kippenberger, Roland Kaufmann, Markus Meissner Department of Dermatology, Venerology and Allergology, University Hospital, Goethe University, Frankfurt am Main, GermanyCorrespondence: Johannes ...
Kleemann J   +5 more
doaj  

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer

open access: yesScientific Reports, 2021
BRAF and NRAS are the most reported mutations associated to melanomagenesis. The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy ...
Gang Yang   +11 more
doaj   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

open access: yesFEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos   +9 more
wiley   +1 more source

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study [PDF]

open access: yes, 2014
Background: Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of ...
N. Davidson (7671467)   +61 more
core   +1 more source

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

open access: yesnpj Precision Oncology
Modern advancements in targeted therapy and immunotherapy have significantly improved survival outcomes for advanced melanoma; however, there remains a need for novel approaches to overcome disease progression and treatment resistance.
Jordan Phillipps   +10 more
doaj   +1 more source

Low Vitamin D Status Predicts Poor Clinical Outcome in Advanced Melanoma Treated With Immune Checkpoint or BRAF/MEK Inhibitors: A Prospective Non-Interventional Side-by-Side Analysis

open access: yesFrontiers in Oncology, 2022
In melanoma and other malignancies, low vitamin D status is associated with increased risk and poor prognosis. However, there are limited data of the impact of 25(OH)D serum concentration (s.c.) on clinical outcome in advanced melanoma.
Jörg Reichrath   +6 more
doaj   +1 more source

Advances in Vaccines for Melanoma

open access: yesHematology/Oncology Clinics of North America
Personalized neoantigen vaccines have achieved major advancements in recent years, with studies in melanoma leading progress in the field. Early clinical trials have demonstrated their feasibility, safety, immunogenicity, and potential efficacy. Advances in sequencing technologies and neoantigen prediction algorithms have substantively improved the ...
Cui, Can   +2 more
openaire   +2 more sources

Combination therapies in advanced melanoma [PDF]

open access: yesMelanoma Management, 2014
Until recently, melanoma represented a significant clinical challenge to oncologists. However, the approval in 2011 of ipilimumab, an anti-CTLA4 monoclonal antibody, and vemurafenib, a BRAF inhibitor, completely changed melanoma management, with both drugs being shown to improve overall survival. The advent of these two drugs, together with the ongoing
openaire   +2 more sources

Home - About - Disclaimer - Privacy